Anne S Tsao1, James Moon2, Ignacio I Wistuba3, Nicholas J Vogelzang4, Gregory P Kalemkerian5, Mary W Redman2, David R Gandara6, Karen Kelly6. 1. Department of Thoracic and Head and Neck Medical Oncology, University of Texas M. D. Anderson Cancer Center, Houston, Texas. Electronic address: astsao@mdanderson.org. 2. SWOG Statistical Center, Seattle, Washington. 3. Department of Translational Molecular Pathology, University of Texas M. D. Anderson Cancer Center, Houston, Texas. 4. Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada. 5. University of Michigan, Ann Arbor, Michigan. 6. University of California Davis Cancer Center, Sacramento, California.
Abstract
INTRODUCTION: In malignant pleural mesothelioma, targeting angiogenesis with cediranib, a vascular endothelial growth factor receptor and platelet-derived growth factor receptor inhibitor, may have therapeutic potential. METHODS: S0905 phase I combined cediranib (two dose cohorts [30 mg and 20 mg daily]) with cisplatin-pemetrexed for six cycles followed by maintenance cediranib in unresectable chemonaive patients with malignant pleural mesothelioma of any histologic subtype. The primary end point established the maximum tolerated dose in combination with cisplatin-pemetrexed in a dose deescalation scheme. RESULTS: A total of 20 patients were enrolled (seven to the 30-mg cohort and 13 to the 20-mag cohort). In the cediranib 30-mg cohort, two of the initial six patients reported dose-limiting toxicities and the dose was deemed too toxic to continue. In the next cohort, two patients experienced dose-limiting toxicities, and thus, the maximum tolerated dose of cediranib was established as 20 mg. During the six cycles of cisplatin-pemetrexed-cediranib, 20 mg, there were grade 3 toxicities (neutropenia and gastrointestinal) and grade 4 thrombocytopenia. No patients had any significant episodes of bleeding. According to the Response Evaluation Criteria in Solid Tumors (n = 17 evaluable patients), the median progression-free survival was 12.8 months (95% confidence interval [CI]: 6.9-17.2); according to the Modified Response Evaluation Criteria in Solid Tumors (n = 19 evaluable patients), the median progression-free survival was 8.6 months (95% CI: 6.1-10.9). For all patients, the disease control rate at 6 weeks was 90% and median overall survival time was 16.2 months (95% CI: 10.5-28.7). CONCLUSIONS: Cediranib combined with cisplatin-pemetrexed has a reasonable toxicity profile and preliminary promising efficacy. The phase II S0905 trial will evaluate the efficacy of the triplet regimen compared with the current standard of care, cisplatin-pemetrexed.
INTRODUCTION: In malignant pleural mesothelioma, targeting angiogenesis with cediranib, a vascular endothelial growth factor receptor and platelet-derived growth factor receptor inhibitor, may have therapeutic potential. METHODS: S0905 phase I combined cediranib (two dose cohorts [30 mg and 20 mg daily]) with cisplatin-pemetrexed for six cycles followed by maintenance cediranib in unresectable chemonaive patients with malignant pleural mesothelioma of any histologic subtype. The primary end point established the maximum tolerated dose in combination with cisplatin-pemetrexed in a dose deescalation scheme. RESULTS: A total of 20 patients were enrolled (seven to the 30-mg cohort and 13 to the 20-mag cohort). In the cediranib 30-mg cohort, two of the initial six patients reported dose-limiting toxicities and the dose was deemed too toxic to continue. In the next cohort, two patients experienced dose-limiting toxicities, and thus, the maximum tolerated dose of cediranib was established as 20 mg. During the six cycles of cisplatin-pemetrexed-cediranib, 20 mg, there were grade 3 toxicities (neutropenia and gastrointestinal) and grade 4 thrombocytopenia. No patients had any significant episodes of bleeding. According to the Response Evaluation Criteria in Solid Tumors (n = 17 evaluable patients), the median progression-free survival was 12.8 months (95% confidence interval [CI]: 6.9-17.2); according to the Modified Response Evaluation Criteria in Solid Tumors (n = 19 evaluable patients), the median progression-free survival was 8.6 months (95% CI: 6.1-10.9). For all patients, the disease control rate at 6 weeks was 90% and median overall survival time was 16.2 months (95% CI: 10.5-28.7). CONCLUSIONS:Cediranib combined with cisplatin-pemetrexed has a reasonable toxicity profile and preliminary promising efficacy. The phase II S0905 trial will evaluate the efficacy of the triplet regimen compared with the current standard of care, cisplatin-pemetrexed.
Authors: Anne S Tsao; Linda Garland; Mary Redman; Kemp Kernstine; David Gandara; Edith M Marom Journal: J Thorac Oncol Date: 2011-03 Impact factor: 15.609
Authors: Jonathan E Dowell; Frank R Dunphy; Robert N Taub; David E Gerber; Likheng Ngov; Jingsheng Yan; Yang Xie; Hedy Lee Kindler Journal: Lung Cancer Date: 2012-07-04 Impact factor: 5.705
Authors: Anne S Tsao; Nusrat Harun; J Jack Lee; John Heymach; Katherine Pisters; Waun Ki Hong; Junya Fujimoto; Ignacio Wistuba Journal: Clin Lung Cancer Date: 2013-12-27 Impact factor: 4.785
Authors: Anne S Tsao; Jieling Miao; Ignacio I Wistuba; Nicholas J Vogelzang; John V Heymach; Frank V Fossella; Charles Lu; Mario R Velasco; Brandy Box-Noriega; James G Hueftle; Shirish Gadgeel; Mary W Redman; David R Gandara; Karen Kelly Journal: J Clin Oncol Date: 2019-08-06 Impact factor: 44.544
Authors: Luciano Mutti; Tobias Peikert; Bruce W S Robinson; Arnaud Scherpereel; Anne S Tsao; Marc de Perrot; Gavitt A Woodard; David M Jablons; Jacinta Wiens; Fred R Hirsch; Haining Yang; Michele Carbone; Anish Thomas; Raffit Hassan Journal: J Thorac Oncol Date: 2018-09 Impact factor: 15.609
Authors: Anna Piotrowska; Fernando Pereira Beserra; Justyna Marta Wierzbicka; Joanna Irena Nowak; Michał Aleksander Żmijewski Journal: Front Oncol Date: 2021-12-24 Impact factor: 6.244